Early evaluation of circulating tumor DNA as marker of therapeutic ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

Purpose: Markers of chemotherapy efficacy in metastatic colorectal cancer (mCRC) are essential for optimization of treatment strategies.

Early changes of ctDNA are strongly correlated with therapeutic efficacy to PST and clinical outcomes in BC patients. The integration of preoperative ctDNA ...

Early evaluation of circulating tumor DNA as marker of therapeutic ...

ctDNA was found to be detected in 51.4% (37/72) of patients before the start of PST in our study. However, baseline ctDNA positivity rate varies significantly ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

We evaluated the applicability of early changes in circulating tumor DNA (ctDNA) as a marker of therapeutic efficacy. Experimental Design ...

Circulating tumor DNA as an early marker of therapeutic response in ...

In this work, we describe the potential role of ctDNA as an early predictor of treatment response of patients with metastatic colorectal cancer (mCRC) ...

Circulating tumor DNA as an early marker of therapeutic response in ...

We describe the potential role of ctDNA as an early predictor of treatment response of patients with metastatic colorectal cancer (mCRC) undergoing ...

Circulating tumor DNA as an early marker of therapeutic response in ...

We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy. Patients and methods: This prospective study involved 53 ...

Correlation between early dynamics in circulating tumour DNA and ...

... tumour DNA (ctDNA) levels were explored as a marker of therapeutic efficacy. ... A ctDNA decline from pre-treatment to first response evaluation ...

Evaluation of Circulating Tumor DNA Levels as a Predictive Marker ...

This phase II trial evaluates circulating tumor deoxyribonucleic acid (ctDNA) levels as a predictive marker on switching treatment earlier in patients with ...

Monitoring of Early Changes of Circulating Tumor DNA in ... - Frontiers

Therefore, ctDNA evaluation has a great potential as a marker for monitoring the disease and course of the treatment (30). It has long been ...

Using Circulating Tumor DNA in Colorectal Cancer: Current and ...

The clearance of ctDNA is also a potential biomarker that could help with early assessment of therapeutic efficacy. ctDNA testing also generally ...

On-treatment measurements of circulating tumor DNA during ...

Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL Study). Clin ...

Circulating Tumor DNA Analyses as Markers of Recurrence Risk ...

Objective To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy ...

Early ctDNA response to chemotherapy. A potential surrogate ...

... treatment and first evaluation ... Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.

Recent Advancements in the Application of Circulating Tumor DNA ...

... early cancer detection, monitoring treatment ... DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.

The interplay of circulating tumor DNA and chromatin modification ...

[113] Moreover, monitoring of circulating DNA is informative for earlier evaluation of the treatment response than the radiographic image [114].

Regulatory implications of ctDNA in immuno-oncology for solid tumors

Early detection of metastatic relapse and monitoring of therapeutic ... circulating tumor DNA for early cancer detection. Cell 2017;168:571 ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

PDF | Background We assessed the potential role of serial circulating tumor DNA (ctDNA) as a biomarker to monitor treatment response to ...

Circulating tumor DNA is a prognostic marker of tumor recurrence in ...

Early evaluation of circulating tumor ... tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.

RAS mutation analysis in circulating tumor DNA from patients with ...

Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res. 2017 ...